AMENDMENTS TO THE CLAIMS

- 1. (Currently Amended) A group of oligonucleotides specifically bind An oligonucleotide sequence that specifically binds to human tumor necrosis factor α (TNF-α), said oligonucleotide sequence being selected from sequences showed in SEQ Nos. 1-28 ID NOs: 1-27 or 28.
- 2. (Withdrawn, Currently Amended) The oligonucleotide sequences sequence as recited claimed in Claim 1, including DNA sequences and RNA sequences, wherein the DNA SEQ No. 1-18 has one of the secondary structures as following wherein SEQ ID NO: 1 and SEQ ID NO: 5 respectively have the following stem-loop structure:

 $\underline{I (SEQ ID NO: 1)} \qquad \underline{II (SEQ ID NO: 5)}.$

3. (Currently Amended) The oligonucleotide sequences sequence as recited claimed in Claim 1, wherein the RNA SEQ No. 19-28 sequence has one of the secondary structures as following SEQ ID NO: 19: and SEQ ID NO: 25 respectively have the following stem-loop structure:

4. (Currently Amended) The oligonucleotide sequences sequence as recited claimed in Claim 1 including a homologue Claim 1, wherein the oligonucleotide sequence comprises a homologue that has 70% homologue homology with and functions identical to the oligonucleotide sequence.

5. (Currently Amended) The oligonucleotides oligonucleotide sequence as recited

claimed in Claim 1, wherein the oligonucleotide sequence comprises including a truncated

oligonucleotide sequence that functions identical to the oligonucleotide sequence.

6. (Currently Amended) The oligonucleotides sequences oligonucleotide sequence as

recited claimed in Claim 1, wherein the oligonucleotide sequence comprises including a

modified oligonucleotides oligonucleotide sequence that functions identical to the

oligonucleotides oligonucleotide sequence.

7. (Currently Amended) A hybridizing oligonucleotides oligonucleotide sequence which

hybridize hybridizes with the oligonucleotides oligonucleotide sequence as recited in Claim 1

under-strict condition.

8. (Currently Amended) A derivated An oligonucleotide sequence derived from the

oligonucleotides oligonucleotide sequence as recited in of Claim 1.

9. (Withdrawn) The application of the oligonucleotides sequence as recited in Claim 1 for

manufacture for therapy and diagnosis of TNF-α related diseases.

10. (New) The oligonucleotide sequence as claimed in Claim 5, wherein the truncated

oligonucleotide sequence is derived from SEQ ID NO: 20, SEQ ID NO: 23, SEO ID NO: 25 or

SEQ ID NO: 26.

JMS/REG/ktp

- 11. (New) An oligonucleotide sequence that specifically binds to human tumor necrosis factor α (TNF- α), said oligonucleotide sequence comprising SEQ ID NO: 25.
- 12. (New) The oligonucleotide sequence as claimed in claim 11, wherein the oligonucleotide sequence has the following stem-loop structure:

13. (New) The oligonucleotide sequence as claimed in claim 11, wherein the oligonucleotide sequence comprises a truncated oligonucleotide sequence that functions identical to the oligonucleotide sequence.

Application No. 10/822,761 Amendment dated December 18, 2006 Reply to Office Action of September 18, 2006 Docket No.: 4533-0108PUS1 Page 8 of 12

14. (New) The oligonucleotide sequence as claimed in Claim 11, wherein the oligonucleotide sequence comprises a homologue that has 70% homology with and functions identical to the oligonucleotide sequence.